Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis

References

• Canellos G, Anderson J, Propert K, et al. Chemotherapy of advanced Hodgkin’s Disease with MOPP, ABVD, or MOPP alternating with ABVD. N Eng J Med. 1992;327: 1478–1484.
   PubMed Web of Science ®Google Scholar
• Chisesi T, Federico M, Levis A, et al. ABVD versus Stanford V versus MEC in unfavourable Hodgkin’s lymphoma: results of a randomised trial. Ann Oncol. 2002;13:102–106.
   PubMed Web of Science ®Google Scholar
• Hoskin P, Lowry L, Horwich A, et al. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin’s lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study. J Clin Oncol. 2009;27:5390–5396.
   PubMed Web of Science ®Google Scholar
• Gobbi P, Levis A, Chisesi T, et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin’s lymphoma: final results of a multicentre randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol. 2005;23:9198–9207.
   PubMed Web of Science ®Google Scholar
• Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009;27:805–811.
   PubMed Web of Science ®Google Scholar
• Duggan D, Petroni G, Johnson J, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s Disease: report of an intergroup trial. J Clin Oncol. 2003;21:607–614.
   PubMed Web of Science ®Google Scholar
• Advani R. Optimal therapy of advanced Hodgkin lymphoma. Hematol Am Soc Hematol Educ Program. 2011;2011: 310–316.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Herbst C, Reiser M, et al. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev. 2008;10:CD003189.
   Google Scholar
• Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433–2453.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33:3199–3212.
   PubMed Web of Science ®Google Scholar
• Azoulay E, Herigault S, Levame M, et al. Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis. Crit Care Med. 2003;31:1442–1448.
   PubMed Web of Science ®Google Scholar
• Martin W, Ristow K, Habermann T, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol. 2005;23:7614–7620.
   PubMed Web of Science ®Google Scholar
• Minuk LA, Monkman K, Chin-Yee IH, et al. Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study. Leuk Lymphoma 2012;53:57–63.
   PubMed Web of Science ®Google Scholar
• Evens AM, Cilley J, Ortiz T, et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol. 2007;137:545–552.
   PubMed Web of Science ®Google Scholar
• Nangalia J, Smith H, Wimperis JZ. Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support. Leuk Lymphoma. 2008;49:1530–1536.
   PubMed Web of Science ®Google Scholar
• Boleti E, Mead GM. ABVD for Hodgkin’s lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol. 2007;18:376–380.
   PubMed Web of Science ®Google Scholar
• Horning S. Risk, cure and complications in advanced Hodgkin disease. Hematology Am Soc Hematol Educ Program. 2007:197–203.
   Google Scholar
• Graczyk J, Cheung MC, Buckstein R, et al. Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis. Leuk Lymphoma 2014;55:56–62.
   PubMed Web of Science ®Google Scholar
• Drug costs catalogue. St-Laurent, Quebec: McKesson Canada; 2012.
   Google Scholar
• Eich HT, Kriz J, Muller RP. Evolution of radiation therapy within the German Hodgkin Study Group trials. J Natl Compr Canc Netw. 2011;9:1073–1080.
   PubMed Web of Science ®Google Scholar
• Koeck J, Abo-Madyan Y, Lohr F, et al. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy. Int J Radiat Oncol Biol Phys 2012;83:268–276.
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2011;118:4363–4365.
   PubMed Web of Science ®Google Scholar
• Ontario Health Insurance (OHIP) Schedule of Benefits and Fees. http://www.health.gov.on.ca/english/providers/program/ohip/sob/physserv/physserv_mn.html.
   Google Scholar
• Lathia N, Mittmann N, DeAngelis C, et al. Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer 2010;116:742–748.
   PubMed Web of Science ®Google Scholar
• Huang TT, Hudson MM, Stokes DC, et al. Pulmonary outcomes in survivors of childhood cancer: a systematic review. Chest 2011;140:881–901.
   PubMed Web of Science ®Google Scholar
• Collard HR, Ward AJ, Lanes S, et al. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ. 2012;15: 829–835.
   PubMedGoogle Scholar
• Wilson EC, Shulgina L, Cahn AP, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial. Pharmacoeconomics 2014;32:87–99.
   PubMed Web of Science ®Google Scholar
• Cheung MC, Hay AE, Crump M, et al. Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplantin for relapsed aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12. J Natl Cancer Inst 2015;107(7).
   Google Scholar
• Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry 2005;187:106–108.
   PubMed Web of Science ®Google Scholar
• Rueda A, Alba E, Ribelles N, et al. Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: a pilot study. J Clin Oncol. 1997;15:1118–1122.
   PubMed Web of Science ®Google Scholar
• Zinzani P, Magagnoli M, Frezza G, et al. ABVD and radiation therapy as first line treatment in advanced Hodgkin's Disease. Leuk Lymphoma 1999;32:553–559.
   PubMed Web of Science ®Google Scholar
• Johnson P, Radford J, Cullen M, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 trial. J Clin Oncol. 2005;23:9208–9218.
   PubMed Web of Science ®Google Scholar
• Abdel Hamid T, El Zawahry H, Khattab N, et al. Prognostic factors of Hodgkin's lymphoma and their impact on resonse to chemotherapy and survival. J Egypt Natl Cancer Inst. 2005;17:9–14.
   PubMedGoogle Scholar
• Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's Disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975;36:252–259.
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Santoro A. ABVD chemotherapy in the treatment of Hodgkin's Disease. Cancer Treat Rev. 1982;9:21–35.
   PubMed Web of Science ®Google Scholar
• Nangalia J, Smith H, Wimperis J. Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support. Leuk Lymphoma 2008;49:1530–1536.
   PubMed Web of Science ®Google Scholar
• Boleti E, Mead G. ABVD for Hodgkin's lymphoma: full dose chemotherapy without dose reductions or growth factors. Ann Oncol. 2007;18:376–380.
   PubMed Web of Science ®Google Scholar
• Chand V, Link B, Ritchie J, et al. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy. Leuk Lymphoma 2006;47:657–663.
   PubMed Web of Science ®Google Scholar
• Canellos G, Duggan D, Johnson J, et al. How important is Bleomycin in the Adriamycin + Bleomycin + Vinblastine + Dacarbazine regimen? J Clin Oncol. 2004;22:1532–1533.
   Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2001;359:2065–2071.
   Web of Science ®Google Scholar
• Martin A, Fernandez-Jiminez M, Caballero M, et al. Long-term follow up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Brit J Haematol. 2001;113:161–171.
   PubMed Web of Science ®Google Scholar
• Moskowitz C, Nimer S, Zelenetz A, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616–623.
   PubMed Web of Science ®Google Scholar
• Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol. 2002;13:1628–1635.
   PubMed Web of Science ®Google Scholar
• Baetz T, Belch A, Couban S, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 2003;14:1762–1767.
   PubMed Web of Science ®Google Scholar
• Bartlett N, Niedzwiedzki D, Johnson J, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol. 2007;18:1071–1079.
   PubMed Web of Science ®Google Scholar
• Proctor S, Jackson G, Lennard A, et al. Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK). Ann Oncol. 2003;14(Suppl. 1):i47–50.
   PubMed Web of Science ®Google Scholar
• Ferme C, Mournier N, Divine M, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol. 2002;20:467–475.
   PubMed Web of Science ®Google Scholar
• Bonfante V, Viviani S, Santoro A, et al. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. Brit J Haematol. 1998;103:533–535.
   PubMed Web of Science ®Google Scholar
• Bonfante V, Viviani S, Devizzi L, et al. High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease. Eur J Haematol Supplementum. 2001;64:51–55.
   PubMedGoogle Scholar
• Chisesi T, Bellei M, Luminari S, et al. Long term follow-up analysis of HD9601 trial comparing ABVD vs Stanford V vs MOPPABVCAD in patients with newly diagnosed advnaced stage Hodgkin lymphoma. A study from the Intergruppo Italiano Linfomi. In: ASH Abstract; 2008.
   Google Scholar
• Majhail N, Bajorunaite R, Lazarus H, et al. Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma. Brit J Haematol. 2009;147:129–139.
   PubMed Web of Science ®Google Scholar
• Evens A, Cilley J, Oritz T, et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Brit J Haematol. 2007;137:545–552.
   PubMed Web of Science ®Google Scholar
• Silvestri F, Fanin R, Velisig M, et al. The role of granulocyte colonly-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's Disease. Tumori 1994;80:453–458.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Herbst C, Reiser M, et al. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev. 2008;4:CD003189.
   PubMed Web of Science ®Google Scholar
• Younes A, Fayad L, Romaguera J, et al. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 2006;42:2976–2981.
   PubMed Web of Science ®Google Scholar
• Ng A, Li S, Neugberg D, et al. A prospective study of pulmonary function in Hodgkin's lymphoma patients. Ann Oncol. 2008;19:1754–1758.
   PubMed Web of Science ®Google Scholar
• Salloum E, Tanoue L, Wackers F, et al. Assessment of cardiac and pulmonary function in adult patients with Hodgkin's disease treated with ABVD of MOPP/ABVD plus adjuvant low dose mediastinal irradiation. Cancer Investig. 1999;17:171–180.
   PubMed Web of Science ®Google Scholar
• Horning S, Adhikari A, Rizk N, et al. Effect of treatment for Hodgkin's disease on pulmonary function: results of a prospective study. J Clin Oncol. 1994;12:297–305.
   PubMed Web of Science ®Google Scholar
• Ng A, Weeks J, Mauch P, et al. Laparotomy versus no laparotomy in the management of early-stage, favorable-prognosis Hodgkin's disease: a decision analysis. J Clin Oncol. 1999;17:241–252.
   PubMed Web of Science ®Google Scholar
• Horning S, Chao N, Negrin R, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997;89:801–813.
   PubMed Web of Science ®Google Scholar
• Linch D, Winfield D, Goldstone A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051–1054.
   PubMed Web of Science ®Google Scholar
• Lyman G, Lalla A, Barron R, et al. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Curr Med Res Opin. 2009;25:401–411.
   PubMed Web of Science ®Google Scholar
• Lyman G, Lalla A, Barron R, et al. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin Therap. 2009;31:1092–1104.
   PubMed Web of Science ®Google Scholar
• Danova M, Chiroli S, Rosti G, et al. Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients. Tumori 2009;95:219–226.
   PubMed Web of Science ®Google Scholar
• Carlson J, Garrison L, Ramsey S, et al. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health 2009;12:20–27.
   PubMed Web of Science ®Google Scholar
• Ramsey S, Liu Z, Boer R, et al. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health 2009;12:217–225.
   PubMed Web of Science ®Google Scholar
• Carlson J, Reyes C, Oestreicher N, et al. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer 2008;61:405–415.
   PubMed Web of Science ®Google Scholar
• Eldar-Lissai A, Cosler L, Culakova E, et al. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 2008;11:172–179.
   PubMed Web of Science ®Google Scholar
• Au H, Golmohammadi K, Younis T, et al. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects. Breast Cancer Res Treat. 2009;114:579–587.
   PubMed Web of Science ®Google Scholar
• Brown R, Hutton J, Burrell A. Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 1;19:1091–1102.
   PubMed Web of Science ®Google Scholar
• Brown R, Hutton J. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anticancer Drugs 1998;9:899–907.
   PubMed Web of Science ®Google Scholar
• Launois R, Reboul-Marty J, Henry B, et al. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics 1996;10:504–521.
   Google Scholar
• Norum J, Angelsen V, Wist E, et al. Treatment costs in Hodgkin's disease: a cost-utility analysis. Eur J Cancer 1996;32A:1510–1517.
   PubMed Web of Science ®Google Scholar
• Kasteng F, Erlanson M, Hagberg H, et al. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden. Acta Oncol. 2008;47:1029–1036.
   PubMed Web of Science ®Google Scholar
• Hayslip J, Simpson K. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission. Clin Lymph Myeloma 2008;8:166–170.
   PubMedGoogle Scholar
• Hornberger J, Best J. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer. 2005;103:1644–1651.
   PubMed Web of Science ®Google Scholar
• Uyl-de Groot C, Hagenbeek A, Verdonck L, et al. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL). Bone Marrow Transpl. 1995;16:463–470.
   PubMed Web of Science ®Google Scholar
• Hornberger J, Reyes C, Lubeck D, et al. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymphoma 2008;49:227–236.
   PubMed Web of Science ®Google Scholar
• Wirt D, Giles F, Oken M, et al. Cost-Effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma. Leuk Lymphoma 2001;40:565–579.
   PubMed Web of Science ®Google Scholar
• Das P, Ng AK, Earle CC, et al. Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis. Ann Oncol. 2006;17:785–93.
   PubMed Web of Science ®Google Scholar
• Dumont S, Jacobs P, Turcotte V, et al. The trajectory of palliative care costs over the last 5 months of life: a Canadian longitudinal study. Palliat Med 2010;24:630–40.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Klar N, Weeks JC, et al. Predicting costs of stem-cell transplantation. J Clin Oncol. 2000;18:64–71.
   PubMed Web of Science ®Google Scholar
• Ianotto JC, Ngo Sack F, Couturier MA, et al. Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery. Leuk Lymphoma. 2014;55:74–77.
   PubMed Web of Science ®Google Scholar
• Sung AD, Grima DT, Bernard LM, et al. Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone. Bone Marrow Transpl. 2013;48:1444–1449.
   PubMed Web of Science ®Google Scholar